Sirenia Capital Management LP Reports 5.3% Stake in Dianthus Therapeutics, Inc.

On May 15, 2026, Sirenia Capital Management LP and Alex Silverstein filed a Schedule 13G with the SEC, reporting a combined beneficial ownership of 2,798,122 shares of Common Stock in Dianthus Therapeutics, Inc. (DNTH). This stake represents approximately 5.3% of the company's outstanding shares. The reported holdings include 500,000 shares of Common Stock issuable upon the exercise of call options. Sirenia Capital Management LP serves as the investment manager for an investment fund and a managed account that hold the securities. Alex Silverstein is the managing member of Sirenia Capital Management GP LLC, the general partner of Sirenia. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The calculation of the ownership percentage is based on an aggregate of 52,942,083 shares outstanding as of early March 2026, accounting for recent offerings and underwriter overallotments. This filing marks a new significant position for the reporting persons in the issuer.